NDAORALTABLETPriority Review
Approved
Jun 2007
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
8/8 — Comprehensive
Priority Review
LETAIRIS (ambrisentan) by Gilead Sciences is endothelin receptor antagonists [moa]. Approved for pulmonary arterial hypertension, pulmonary hypertension. First approved in 2007.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LETAIRIS (ambrisentan) is an oral small-molecule endothelin receptor antagonist approved by the FDA in June 2007 for the treatment of pulmonary arterial hypertension (PAH). It works by blocking endothelin receptors, which reduces vasoconstriction and improves hemodynamics in PAH patients. The product is currently in its peak lifecycle stage, indicating mature market penetration and established clinical utility in the PAH treatment landscape.
$0.1BPart D
5.4 years to LOEMechanism of Action
Endothelin Receptor Antagonists
Pharmacologic Class:
Endothelin Receptor Antagonist
Indications (2)
Worked on LETAIRIS at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.